Yue Li

Title: The Innovative Contributions of Yue Li

Introduction

Yue Li is a prominent inventor based in Bedford, MA (US). She has made significant contributions to the field of biotechnology, particularly in the development of angiogenesis inhibitors. With a total of 2 patents, her work has the potential to impact therapeutic approaches in various medical conditions.

Latest Patents

Yue Li's latest patents include innovative methods for the expression and export of angiogenesis inhibitors as immunofusins. The first patent describes a fusion protein that comprises an immunoglobulin Fc region linked to a first target protein, specifically a collagen XVIII fragment, preferably endostatin. This invention aims to enhance the delivery and efficacy of angiogenesis inhibitors. The second patent focuses on a homodimeric protein that exhibits angiogenesis inhibiting activity. This protein consists of two identical fusion proteins bound together, each containing an immunoglobulin Fc region and a first target protein with angiogenesis inhibiting properties, selected from plasminogen fragments and collagen XVIII fragments.

Career Highlights

Yue Li is currently associated with Merck Patent GmbH, where she continues to advance her research and development efforts. Her work is characterized by a strong focus on innovative solutions that address critical health challenges.

Collaborations

Yue has collaborated with notable colleagues, including Kin-Ming Lo and Stephen D. Gillies, to further her research initiatives and enhance the impact of her inventions.

Conclusion

Yue Li's contributions to the field of biotechnology through her patents on angiogenesis inhibitors demonstrate her commitment to innovation and improving health outcomes. Her work continues to inspire advancements in medical research and therapeutic development.